| Sr. No. |
Name of the Project |
Year
of Sanction |
Principal Investigators |
Duration |
Funding Agency |
Amount Sanctioned (Rs) |
| 1 |
A phase III Study to evaluate Immune Non Inferiority and safety of the All In One Liquid formulation of a Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) to a licensed vaccine Rotateq when administered concomitantly with other routinely recommended vaccines for the age. |
2014-2015 |
Dr. Sharad Agarkhedkar ,
Dr. Shalaka Agarkhedkar,
Dr. Renuka Jadhav |
1yr |
Shantha Biotechnics Limited, Hyderabad,
Telangana, India |
22,54,000/- |
| 2 |
A Phase 4/3, Open-Label, Single-Arm, multicenter Study to Describe the Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Adults 50 to 65 Years of Age and in Children 6 to 17 Years of Age in India |
2014-2015 |
Dr. Sharad Agarkhedkar,
Dr. Shalaka Agarkhedkar,
Dr. Renuka Jadhav |
1yr |
Wyeth Limited (Subsidiary of Pfizer Inc.) |
11,37,816/- |
| 3 |
A Phase III Bridging study to evaluate Immunogenicity and Safety of a Pentavalent vaccine (DTwP-HepB-Hib) Shan5 (with Shantha pertussis) as compared to the licensed vaccine, Shan5 (with imported pertussis) when administered as three dose primary series at 6-8, 10-12 and 14-16 Weeks of Age in Healthy Indian Infants |
2014-2015 |
Dr.Sharad Agarkhedkar, Dr.Shalaka Agarkhedkar |
1yr |
Shantha Biotechnics Pvt Ltd, Hyderabad, Telangana |
9,12,000/- |
| 4 |
Compartive evaluation of immunogenicity of bivalent oral poliovirus vaccine (bOPV) and monovalent oral poliovirus vaccine type 1 (mOPV1) when administered in the EPI schedule with a dose of inactivated polio vaccine (IPV) at week 14 and assessement of immunogenicity of IPV only schedule in the EPI: A multicentric open label randomized controlled trial |
2016-2017 |
Dr. Sharad Agarkhedkar
Dr. Vineeta Pande
Dr. Shalaka Agarkhedkar
|
1yrs |
WHO clinical trial |
644500/- |
| 5 |
Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Subjects Aged 6 Months or Older in India |
2016-2017 |
Dr.Sharad Agarkhedkar, Dr.Shalaka Agarkhedkar |
1yrs |
Sanofi Pasteur SA |
2,62,782/- |
| 6. |
Health care –Associated sepsis in the Neonatol Intensive Care unit in Pune India, in Assossion |
|
Dr. S.R.Agarkhedkar
Dr. Sudhir Malwade
|
|
John Hopkins University Baltimore, USA. |
29,51,168 |
| 7 |
.A randomized, double-blind,placebo-controlled,parallel goup,multicenter,comparative study to assess the efficacy and safety of Entergermina in combination with oral rehydration theraphy (ORT) and Zinc verus placebo in combination with ORT and zinc administered for 5 days in the tretment of acute diarrhea in children |
2019-2020 |
Dr.Sharad Agarkhedkar, Dr.Shalaka Agarkhedkar
Dr.Vineeta Pande
Dr. Renuka Jdhav |
1 year |
Sanofi |
1 Crore |
| 8 |
A Phase III, Open Label, Randomized, Multi-Centric, Active-Controlled, Clinical Trial to evaluate the immune response and safety of SIIPL’s Freeze Dried Live Attenuated Human Seasonal Trivalent Vaccine (LAIV-FD) among healthy Indian individuals >2 years of age |
2019-2020 |
Dr.Sharad Agarkhedkar, Dr.Shalaka Agarkhedkar |
1 year |
Serum Institute |
30,000,00 |
| 9 |
3 Project Ongoing
1.N-Cov (Zydus)
2. Active study
(N/H)
3. CDCD Mdnupirawis |
2021 |
|
|
|
|
|
10
|
To evaluate efficacy, safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine
|
|
Dr. Sharad Agarkhedkar ,
Dr. Shalaka Agarkhedkar,
|
Zycovid – March 2021 to August 2022
ongoing
|
Cadila Healthcare Limited, Ahmedabad, India
|
10,000 per subject enrolled
|
|
11
|
Clinical trial of Molnupiravir 800 mg capsules in confirmed RT-PCR positive patients with mild COVID-19.
|
|
Dr. Sharad Agarkhedkar,
Dr. Shalaka Agarkhedkar,
|
May 2021 to Sep 2021 (Subjects visits completed) , study is not yet closed out
|
NATCO Pharma Limited NATCO House Road No.2, Banjara Hills Hyderabad
|
32,00,000/-
|
|
12
|
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)
|
|
Dr. S. R. Agarkhedkar, Dr. Shalaka Agarkhedkar
|
Enrolment for the ACTIV-2 trial has been temporarily paused, effective as of 20 January 2022 globally. Trial did not start in India
|
National Institute of Allergy and Infectious Diseases.
|
4300000/-
|
|
13
|
To Evaluate the Efficacy and Safety of Rilematovir in Infants and Children with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
|
|
Dr. S. R. Agarkhedkar, Dr. Shalaka Agarkhedkar
|
Strategic decision to discontinue the study by Sponsor in Jan 2022
|
Johnson & Johnson Private Limited
|
3000000/-
|
|
14
|
To evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive – COVID 19 Vaccine
|
|
Dr. S. R. Agarkhedkar, Dr. Shalaka Agarkhedkar
|
Not yet started
|
Johnson & Johnson Private Limited
|
3165000/-
|
|
15
|
A Prospective, Randomized, Double-blind, Placebo controlled, Phase-II by III Study to Evaluate Safety, Reactogenicity, Tolerability and Immunogenicity of CORBEVAX Vaccine in Children and Adolescents
|
|
Dr. S. R. Agarkhedkar, Dr. Shalaka Agarkhedkar
|
Dec.2021 to Aug 2022 - Ongoing
|
Biological E. Ltd, Hyderabad, Telangana
|
|
